'AI Supercharges Drug Discoveries, Potentially Changing Medicine' - Semafor
Portfolio Pulse from Happy Mohamed
Biotech company Recursion has used artificial intelligence (AI) and supercomputers to predict new possible chemical interactions for drug discovery. The company combined a database of 15,000 human proteins from Google's AI research organization, DeepMind, with another containing 36 billion molecules. The data was processed using a supercomputer and cloud computing power from Nvidia. Recursion, which conducts about 2.2 million experiments per week, has collected 25 petabytes of data. However, the company now faces the challenge of turning AI predictions into physical lab tests and getting them through FDA clinical trials.
August 09, 2023 | 4:36 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Recursion's use of AI for drug discovery could potentially revolutionize the pharmaceutical industry, but the company faces regulatory hurdles and the challenge of turning AI predictions into physical lab tests.
Recursion's innovative use of AI for drug discovery could potentially revolutionize the pharmaceutical industry, which could positively impact its stock. However, the company faces regulatory hurdles and the challenge of turning AI predictions into physical lab tests, which could negatively impact its stock.
CONFIDENCE 70
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Google's AI research organization, DeepMind, has contributed to Recursion's drug discovery process, potentially enhancing Google's reputation in the AI and biotech sectors.
Google's DeepMind's involvement in Recursion's drug discovery process could enhance Google's reputation in the AI and biotech sectors, potentially leading to more partnerships and collaborations, which could positively impact Google's stock.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 70
POSITIVE IMPACT
Nvidia's supercomputer and cloud computing power were used in Recursion's drug discovery process, which could boost Nvidia's reputation in the AI and biotech sectors.
Nvidia's involvement in Recursion's drug discovery process could enhance Nvidia's reputation in the AI and biotech sectors, potentially leading to more partnerships and collaborations, which could positively impact Nvidia's stock.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 70